The effect of the trifunctional anti-EpCAM antibody catumaxomab on the development of tumor-specific immune responses in patients with gastric cancer.

被引：1
|
作者：
Reinhard, H.
Meyer, S. K.
Bartels, K.
Fischer, R.
Seimetz, D.
Bokemeyer, C.
Atanackovic, D.
机构：
[1] Univ Med Ctr Hamburg Eppendorf, Univ Canc Ctr Hamburg, Hamburg, Germany
[2] Univ Med Ctr Hamburg Eppendorf, Univ Canc Ctr, Hamburg, Germany
[3] Fresenius Biotech GmbH, Munich, Germany
[4] Univ Med Ctr Hamburg Eppendorf, Hamburg, Germany
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2011年 / 29卷 / 15期
关键词：
D O I：
10.1200/jco.2011.29.15_suppl.2601
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
2601
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Randomised phase II trial to investigate catumaxomab (anti-EpCAM x anti-CD3) for treatment of peritoneal carcinomatosis in patients with gastric cancer
    Knoedler, Maren
    Koerfer, Justus
    Kunzmann, Volker
    Trojan, Joerg
    Daum, Severin
    Schenk, Michael
    Kullmann, Frank
    Schroll, Sebastian
    Behringer, Dirk
    Stahl, Michael
    Al-Batran, Salah-Eddin
    Hacker, Ulrich
    Ibach, Stefan
    Lindhofer, Horst
    Lordick, Florian
    BRITISH JOURNAL OF CANCER, 2018, 119 (03) : 296 - 302
  • [22] Treatment of peritoneal carcinomatosis due to GI-tract cancer by intraperitoneal application of the trifunctional antibody catumaxomab (anti-EpcAM x anti-CD3): Results of a phase VII trial.
    Stroehlein, MA
    Lordick, F
    Ruettinger, D
    Gruetzner, U
    Menzel, H
    Bartelheim, K
    Jaeger, M
    Lindhofer, H
    Jauch, KW
    Peschel, C
    Heiss, MM
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 173S - 173S
  • [23] Immune stimulatory effect of anti-EpCAM immunotoxin - improved overall survival of metastatic colorectal cancer patients
    Andersson, Yvonne
    Inderberg, Else Marit
    Kvalheim, Gunnar
    Herud, Theodor Malmer
    Engebraatena, Olav
    Flatmark, Kjersti
    Dueland, Svein
    Fodstad, Oystein
    ACTA ONCOLOGICA, 2020, 59 (04) : 404 - 409
  • [24] Induction of anti-tumor immunity by concomitant cell therapy and trifunctional bispecific antibody anti-(CD3 x Anti-EpCAM)
    Slavin, Shimon
    Lindhofer, Horst
    Yacovlev, Elena
    Gelfand, Yael
    Morecki, Shoshana
    JOURNAL OF IMMUNOTHERAPY, 2006, 29 (06) : 676 - 676
  • [25] The molecular mechanisms of EpCAM in regulating tumor progression and development of anti-EpCAM antibodies for colon cancer diagnosis and therapy
    Wu, H-C.
    Liang, K. H.
    Hsieh, H. P.
    Li, W. S.
    ANNALS OF ONCOLOGY, 2019, 30 : 786 - 786
  • [26] Explorative trial to investigate catumaxomab (anti-EpCAM x anti-CD3) for treatment of peritoneal carcinomatosis in patients with gastric adenocarcinoma prior to gastrectomy
    Knoedler, M.
    Koerfer, J.
    Kunzmann, V.
    Trojan, J.
    Daum, S.
    Schenk, M.
    Kullmann, F.
    Schroll, S.
    Behringer, D.
    Stahl, M.
    Al-Batran, S. -E.
    Hacker, U.
    Lordick, F.
    ONCOLOGY RESEARCH AND TREATMENT, 2017, 40 : 158 - 158
  • [27] Effective relief of malignant ascites in patients with advanced ovarian cancer by a trifunctional anti-EpCAM x anti-CD3 antibody:: A phase I/II study
    Burges, Alexander
    Wimberger, Pauline
    Kuemper, Carolin
    Gorbounova, Vera
    Sommer, Harald
    Schmalfeldt, Barbara
    Pfisterer, Jacobus
    Lichinitser, Michail
    Makhson, Anatoliy
    Moiseyenko, Vladimir
    Lahr, Angelika
    Schulze, Elisabeth
    Jaeger, Michael
    Stroehlein, Michael A.
    Heiss, Markus Maria
    Gottwald, Thomas
    Lindhofer, Horst
    Kimmig, Rainer
    CLINICAL CANCER RESEARCH, 2007, 13 (13) : 3899 - 3905
  • [28] Intraperitoneal immunotherapy with the bispecific anti-EpCAM x anti-CD3 directed antibody catumaxomab for patients with peritoneal carcinomatosis from gastric cancer: Final results of a randomized phase II AIO trial.
    Lordick, Florian
    Kunzmann, Volker
    Trojan, Jorg
    Daum, Severin
    Schenk, Michael
    Kullmann, Frank
    Schroll, Sebastian
    Behringer, Dirk M.
    Stahl, Michael
    Al-Batran, Salah-Eddin
    Ibach, Stefan
    Koerfer, Justus
    Knoedler, Maren Kristina
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (04)
  • [29] Tolerability and efficacy of the trifunctional antibody removab® (anti-EpCAM x anti-CD3) in patients with malignant ascites due to ovarian cancer: Results of a phase I/II study
    P Wimberger
    A Burges
    V Gorbounova
    H Sommer
    B Schmalfeldt
    J Pfisterer
    M Lichinitser
    A Makhson
    M Ströhlein
    W Eiermann
    M Biakhov
    V Moiseenko
    A du Bois
    R Kimmig
    Cancer Cell International, 4 (Suppl 1)
  • [30] The trifunctional antibody catumaxomab: correlation between immunological reactivity and clinical outcome in patients with malignant ascites due to gastric cancer
    Ott, M.
    Lindhofer, H.
    Hennig, M.
    Essing, M.
    Martinius, H.
    Klein, A.
    Seimetz, D.
    ONKOLOGIE, 2010, 33 : 115 - 115
12345